All this evidence points to the need to develop TNFR2-targeted therapy to diminish tumor-infiltrating Tregs, to impair MDSCs differentiation and endothelial cell neovascularization and to directly attack TNFR2-expressing tumor cells. This evidence concerns the gene TNFRSF1B and neoplasm.